Modified microsample ACT test for heparin monitoring

Chi Miau Pan, David Jobes, Dan Van Riper, John David Ogilby, Chung Yuan Lin, Jan Horrow, Roger S Blumenthal, Marsha Mendoza, Frank LaDuca

Research output: Contribution to journalArticle

Abstract

The activated clotting time (ACT) is a standard method of heparin monitoring during cardiac angioplasty and cardiac surgery. A modified ACT (ACT+) which employs a microsample blood volume (0.05 ml) and yields faster clotting time results than a conventional Hemochron ACT was evaluated and compared to the standard ACT. The ACT+, determined using a single channel general purpose analyzer (Hemochron Jr.), employs a plastic cuvette containing dried ACT reagents (kaolin-silica-phospholipid). In vitro evaluation of heparinized normal donor blood demonstrated the test insensitivity to aprotinin. Using split blood specimens, duplicate ACT and ACT+ were performed (n=92) and a correlation between the two was established. In evaluation of 79 cardiac surgery and 53 angioplasty patients, good correlation was observed between ACT+ and Hemochron ACT (r=0.93, n=574). Mean versus difference plots demonstrated an improved reproducibility of the ACT+ (Mean SD=35 seconds) compared to the ACT (Mean SD=53 seconds), presumably due to automation of the blood sample sizing and blood/reagent mixing. These studies indicate that the microsample ACT+ is an alternative to the conventional ACT with an advantage of small sample requirement and rapid reproducible results.

Original languageEnglish (US)
Pages (from-to)16-20
Number of pages5
JournalJournal of Extra-Corporeal Technology
Volume28
Issue number1
StatePublished - 1996
Externally publishedYes

Fingerprint

Heparin
Angioplasty
Thoracic Surgery
Kaolin
Aprotinin
Automation
Hematologic Tests
Blood Volume
Silicon Dioxide
Plastics
Phospholipids
Tissue Donors

Keywords

  • activated clotting time
  • anticoagulation
  • aprotinin
  • dose-response
  • heparin

ASJC Scopus subject areas

  • Medicine (miscellaneous)

Cite this

Pan, C. M., Jobes, D., Van Riper, D., Ogilby, J. D., Lin, C. Y., Horrow, J., ... LaDuca, F. (1996). Modified microsample ACT test for heparin monitoring. Journal of Extra-Corporeal Technology, 28(1), 16-20.

Modified microsample ACT test for heparin monitoring. / Pan, Chi Miau; Jobes, David; Van Riper, Dan; Ogilby, John David; Lin, Chung Yuan; Horrow, Jan; Blumenthal, Roger S; Mendoza, Marsha; LaDuca, Frank.

In: Journal of Extra-Corporeal Technology, Vol. 28, No. 1, 1996, p. 16-20.

Research output: Contribution to journalArticle

Pan, CM, Jobes, D, Van Riper, D, Ogilby, JD, Lin, CY, Horrow, J, Blumenthal, RS, Mendoza, M & LaDuca, F 1996, 'Modified microsample ACT test for heparin monitoring', Journal of Extra-Corporeal Technology, vol. 28, no. 1, pp. 16-20.
Pan CM, Jobes D, Van Riper D, Ogilby JD, Lin CY, Horrow J et al. Modified microsample ACT test for heparin monitoring. Journal of Extra-Corporeal Technology. 1996;28(1):16-20.
Pan, Chi Miau ; Jobes, David ; Van Riper, Dan ; Ogilby, John David ; Lin, Chung Yuan ; Horrow, Jan ; Blumenthal, Roger S ; Mendoza, Marsha ; LaDuca, Frank. / Modified microsample ACT test for heparin monitoring. In: Journal of Extra-Corporeal Technology. 1996 ; Vol. 28, No. 1. pp. 16-20.
@article{5dba2d19f6744d0f9124e1b556c79694,
title = "Modified microsample ACT test for heparin monitoring",
abstract = "The activated clotting time (ACT) is a standard method of heparin monitoring during cardiac angioplasty and cardiac surgery. A modified ACT (ACT+) which employs a microsample blood volume (0.05 ml) and yields faster clotting time results than a conventional Hemochron ACT was evaluated and compared to the standard ACT. The ACT+, determined using a single channel general purpose analyzer (Hemochron Jr.), employs a plastic cuvette containing dried ACT reagents (kaolin-silica-phospholipid). In vitro evaluation of heparinized normal donor blood demonstrated the test insensitivity to aprotinin. Using split blood specimens, duplicate ACT and ACT+ were performed (n=92) and a correlation between the two was established. In evaluation of 79 cardiac surgery and 53 angioplasty patients, good correlation was observed between ACT+ and Hemochron ACT (r=0.93, n=574). Mean versus difference plots demonstrated an improved reproducibility of the ACT+ (Mean SD=35 seconds) compared to the ACT (Mean SD=53 seconds), presumably due to automation of the blood sample sizing and blood/reagent mixing. These studies indicate that the microsample ACT+ is an alternative to the conventional ACT with an advantage of small sample requirement and rapid reproducible results.",
keywords = "activated clotting time, anticoagulation, aprotinin, dose-response, heparin",
author = "Pan, {Chi Miau} and David Jobes and {Van Riper}, Dan and Ogilby, {John David} and Lin, {Chung Yuan} and Jan Horrow and Blumenthal, {Roger S} and Marsha Mendoza and Frank LaDuca",
year = "1996",
language = "English (US)",
volume = "28",
pages = "16--20",
journal = "Journal of Extra-Corporeal Technology",
issn = "0022-1058",
publisher = "American Society of Extra-Corporeal Technology",
number = "1",

}

TY - JOUR

T1 - Modified microsample ACT test for heparin monitoring

AU - Pan, Chi Miau

AU - Jobes, David

AU - Van Riper, Dan

AU - Ogilby, John David

AU - Lin, Chung Yuan

AU - Horrow, Jan

AU - Blumenthal, Roger S

AU - Mendoza, Marsha

AU - LaDuca, Frank

PY - 1996

Y1 - 1996

N2 - The activated clotting time (ACT) is a standard method of heparin monitoring during cardiac angioplasty and cardiac surgery. A modified ACT (ACT+) which employs a microsample blood volume (0.05 ml) and yields faster clotting time results than a conventional Hemochron ACT was evaluated and compared to the standard ACT. The ACT+, determined using a single channel general purpose analyzer (Hemochron Jr.), employs a plastic cuvette containing dried ACT reagents (kaolin-silica-phospholipid). In vitro evaluation of heparinized normal donor blood demonstrated the test insensitivity to aprotinin. Using split blood specimens, duplicate ACT and ACT+ were performed (n=92) and a correlation between the two was established. In evaluation of 79 cardiac surgery and 53 angioplasty patients, good correlation was observed between ACT+ and Hemochron ACT (r=0.93, n=574). Mean versus difference plots demonstrated an improved reproducibility of the ACT+ (Mean SD=35 seconds) compared to the ACT (Mean SD=53 seconds), presumably due to automation of the blood sample sizing and blood/reagent mixing. These studies indicate that the microsample ACT+ is an alternative to the conventional ACT with an advantage of small sample requirement and rapid reproducible results.

AB - The activated clotting time (ACT) is a standard method of heparin monitoring during cardiac angioplasty and cardiac surgery. A modified ACT (ACT+) which employs a microsample blood volume (0.05 ml) and yields faster clotting time results than a conventional Hemochron ACT was evaluated and compared to the standard ACT. The ACT+, determined using a single channel general purpose analyzer (Hemochron Jr.), employs a plastic cuvette containing dried ACT reagents (kaolin-silica-phospholipid). In vitro evaluation of heparinized normal donor blood demonstrated the test insensitivity to aprotinin. Using split blood specimens, duplicate ACT and ACT+ were performed (n=92) and a correlation between the two was established. In evaluation of 79 cardiac surgery and 53 angioplasty patients, good correlation was observed between ACT+ and Hemochron ACT (r=0.93, n=574). Mean versus difference plots demonstrated an improved reproducibility of the ACT+ (Mean SD=35 seconds) compared to the ACT (Mean SD=53 seconds), presumably due to automation of the blood sample sizing and blood/reagent mixing. These studies indicate that the microsample ACT+ is an alternative to the conventional ACT with an advantage of small sample requirement and rapid reproducible results.

KW - activated clotting time

KW - anticoagulation

KW - aprotinin

KW - dose-response

KW - heparin

UR - http://www.scopus.com/inward/record.url?scp=0029929697&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029929697&partnerID=8YFLogxK

M3 - Article

VL - 28

SP - 16

EP - 20

JO - Journal of Extra-Corporeal Technology

JF - Journal of Extra-Corporeal Technology

SN - 0022-1058

IS - 1

ER -